KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Return on Sales: 2009-2025

Historic Return on Sales for Acadia Pharmaceuticals (ACAD) over the last 15 years, with Sep 2025 value amounting to 0.25%.

  • Acadia Pharmaceuticals' Return on Sales rose 11.00% to 0.25% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.25%, marking a year-over-year increase of 11.00%. This contributed to the annual value of 0.24% for FY2024, which is 32.00% up from last year.
  • According to the latest figures from Q3 2025, Acadia Pharmaceuticals' Return on Sales is 0.25%, which was up 14.40% from 0.22% recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Return on Sales ranged from a high of 0.25% in Q3 2025 and a low of -0.57% during Q1 2021.
  • Moreover, its 3-year median value for Return on Sales was 0.03% (2024), whereas its average is 0.03%.
  • In the last 5 years, Acadia Pharmaceuticals' Return on Sales declined by 7bps in 2022 and then surged by 37bps in 2024.
  • Over the past 5 years, Acadia Pharmaceuticals' Return on Sales (Quarterly) stood at -0.35% in 2021, then declined by 7bps to -0.42% in 2022, then spiked by 33bps to -0.08% in 2023, then skyrocketed by 32bps to 0.24% in 2024, then grew by 11bps to 0.25% in 2025.
  • Its Return on Sales was 0.25% in Q3 2025, compared to 0.22% in Q2 2025 and 0.23% in Q1 2025.